Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05411133
Status:
RECRUITING
Last Update Posted:
2024-01-23
First Post:
2022-05-25
Brief Title:
Treatment of Cabotamig ARB202 in Advanced Gastrointestinal Cancer Patients
Sponsor:
Arbele Pty Ltd
Organization:
Arbele Limited
Study Overview
Official Title:
A Phase 1 First-in-human Study of Cabotamig ARB202 Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to find out
1 The tolerability of Cabotamig ARB202 in adults with advanced solid gastrointestinal tumors who failed the standard treatment People can participate if their tumor has the CDH17 marker
2 To find out how study drug is broken down in the body
3 To know the effects of the study drug on the tumor
1 The tolerability of Cabotamig ARB202 in adults with advanced solid gastrointestinal tumors who failed the standard treatment People can participate if their tumor has the CDH17 marker
2 To find out how study drug is broken down in the body
3 To know the effects of the study drug on the tumor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None